Cue Biopharma’s chronic spontaneous urticaria program received mid-stage reinforcement after a Phase 2 readout of CUE-221 in moderate-to-severe disease. The study met key efficacy targets, including improvements in hives severity and complete response measures, alongside a favorable overall safety profile. The company’s updated clinical direction emphasizes moving forward toward a phase IIb/III program in CSU, following earlier pivot signals toward immunology. Market focus is likely to center on differentiating CUE-221 in a crowded allergic-inflammation space and on the durability of response. A second, closely related report reiterated the same CSU Phase 2 outcome while noting the equity reaction as shares declined despite the positive clinical signal.